North Central Cancer Treatment Group

北中央癌症治疗小组

• 批准号: 7933204
• 负责人: JAN C BUCKNER
• 金额: $ 22.5万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7933204
• 关键词: Advocate; Area; Biological; Cancer Biology; Cancer Control; Cancer Patient; Clinical; Clinical Research Associate; Clinical Trials; Collaborations; Communication; Community Clinical Oncology Program; Concept Review; Data Collection; Development; Discipline; Disease; Education; Goals; Individual; Laboratories; Laboratory Study; Lead; Leadership; Letters; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Methodology; Methods; Modality; Nature; North Central Cancer Treatment Group; Oncologic Nursing; Oncology Nurse; Operative Surgical Procedures; Outcome; Pathology; Patients; Phase; Process; Protocols documentation; Publications; Quality Control; Quality of life; Radiation Oncology; Research; Research Design; Research Infrastructure; Research Personnel; Resources; Review Committee; Techniques; Translational Research; Work; anticancer research; base; cancer health disparity; cancer prevention; cancer therapy; improved; malignant breast neoplasm; medical specialties; member; multidisciplinary; neuro-oncology; novel therapeutics; programs; protocol development; quality assurance; research study; sample collection; statistics; symptom management; translational study; treatment trial; tumor

Description (provided by applicant): The specific aims of the North Central Cancer Treatment Group (NCCTG) are: 1. to improve the duration and quality of life of cancer patients by performing high-quality multidisciplinary cancer treatment trials, 2. to improve the understanding of cancer biology and the biological consequences of treatment by conducting relevant correlative laboratory studies in conjunction with the clinical trials, 3. to improve methods for performing clinical trials by analysis of patient, tumor, and treatment variables in association with clinical outcomes, and 4. to provide an infrastructure for studies of cancer prevention and symptom management. These aims are accomplished through the efforts of four Disease Committees (Breast Cancer, Gastrointestinal Cancer, Lung Cancer, and Neuro-oncology), three Discipline-oriented Scientific Committees (Novel Therapeutics, Quality of Life, and Cancer Control), three Modality Committees (Surgery, Radiation Oncology, and Pathology), Statistics, and five Core Function Committees (Audit, Oncology Nursing Board, Clinical Research Associate (CRA) Board, Cancer Health Disparities, and Patient Advocate). The Disease Committees are responsible for developing and implementing clinical and translational research studies for their respective disease entities in collaboration with Modality, Discipline-oriented Scientific, and Core Function Committees. Modality Committees provide scientific expertise to Disease and Discipline-oriented Scientific Committees, develop quality control standards and provide quality control for individual studies, promote member education and conduct research studies appropriate for their specialty. Discipline-oriented Scientific Committees provide scientific expertise to Disease and Modality Committees and conduct research studies appropriate for their respective disciplines. Core Function Committees assist in protocol development, conduct, and quality assurance appropriate to their areas of expertise. The Group Statistician designates a specific statistician to work with each committee on an ongoing basis to collaborate in letter of intent and concept development, study design, data collection, analysis, presentation and publication. Given the multidisciplinary nature of clinical and translational cancer research, productive communication and interactions among these committees is necessary in order to reach the scientific goals of the Group. The framework for these interactions within NCCTG is illustrated in Table 1, and is described in more detail within the research plans of individual committees. The overarching scientific priority for NCCTG is to conduct high-quality phase II and phase IIII clinical and translational studies appropriate for the community oncology setting. The Translational Research Coordinating Committee serves in an advisory capacity to Group leadership, including NCCTG Committee leaders. The purpose of the committee is to provide scientific and technical advice related to the development and implementation of translational research studies conducted by other committees. Members of the Translational Research Coordinating Concept review concept proposals and protocols in order to assess their scientific merit, recommend additional translational objectives that may be appropriate for a particular protocol, provide advice regarding appropriate laboratory methodology, and identify emerging themes among individual committees that will lead to collaborations among separate committees. Dr. Wilma Lingle, co-director of the NCCTG Biospecimen Resource, also serves on the Translational Research Coordinating Committee and reviews concepts and protocols with translational aims to provide advice concerning appropriate specimen collection, processing techniques, and transport.

描述（由申请人提供）：北中央癌症治疗组（NCCTG）的具体目的是：1。通过进行高质量的多学科癌症治疗试验，以提高癌症患者的持续时间和质量，2。通过与临床试验结合进行相关的相关实验室研究，了解癌症生物学和治疗的生物学后果，3。通过分析患者，肿瘤和治疗变量与临床结局相关，改善进行临床试验的方法，以及4为预防癌症和症状管理提供基础设施。这些目标是通过四个疾病委员会（乳腺癌，胃肠癌，肺癌和神经肿瘤学），三个面向学科的科学委员会（新的治疗学，生活质量和癌症控制），三个模态委员会（三个模式委员会（手术，放射肿瘤学和病理学），统计和五个核心功能委员会（审计，肿瘤护理委员会，临床研究助理（CRA）委员会，癌症健康差异和患者倡导者）。疾病委员会负责与模式，面向学科的科学和核心功能委员会合作为各自疾病实体开发和实施临床和翻译研究。模式委员会为疾病和纪律方面的科学委员会提供科学专业知识，制定质量控制标准并为个人研究提供质量控制，促进会员教育并进行适合其专业的研究。面向纪律的科学委员会为疾病和方式委员会提供科学专业知识，并进行适合各自学科的研究。核心功能委员会协助协议开发，行为和质量保证，适合其专业知识领域。该小组统计学家指定了一个特定的统计学家与每个委员会合作，以在意图和概念开发，研究设计，数据收集，分析，演示和出版物中合作。鉴于临床和转化癌症研究的多学科性质，为了实现该小组的科学目标，必须进行这些委员会之间的生产沟通和互动。表1中说明了NCCTG中这些相互作用的框架，并在单个委员会的研究计划中进行了更详细的描述。 NCCTG的总体科学优先级是进行高质量的II期和IIII期临床和转化研究，适用于社区肿瘤学的环境。转化研究协调委员会以咨询能力为团体领导，包括NCCTG委员会领导人。委员会的目的是提供与其他委员会进行的转化研究的发展和实施有关的科学和技术建议。转化研究协调概念审查概念提案和协议的成员，以评估其科学功绩，建议可能适合特定协议的其他翻译目标，提供有关适当的实验室方法论的建议，并确定各个委员会之间的新兴主题在单独的委员会之间进行合作。 NCCTG BioSCECECECECEMEN资源的联合主任Wilma Lingle博士也是转化研究协调委员会的工作，并审查了概念和协议的转化旨在提供有关适当的标本收集，处理技术和运输的建议。